Paper of the Day - Pioglitazone lowers CV risk in diabetics with CKD
Treating patients with diabetes and chronic kidney disease with pioglitazone lowers their risk of cardiovascular event.
German researchers analysed data from the 5154 patients with Type 2 diabetes and macrovascular disease treated with pioglitazone, and compared the data with patients given a placebo.
The 597 patients who had chronic kidney disease (defined as an eGFR ?60ml ml/min/1.73m2) were significantly more likely to die or experience a major cardiovascular event reach than those without CKD.
After treatment with pioglitazone, 23.7% and 14.6% of CKD patients met the primary and secondary endpoints respectively, compared with 30.7% and 21.4% of controls treated with placebo.
Patients treated with pioglitazone also had better kidney function, with an eGFR that decreased by 0.8 ml ml/min/1.73m2, compared with the control group.
Christian Schneider, from the University of Cologne in Germany, concluded: 'Patients who had CKD and were treated with pioglitazone were less likely to reach the composite end point of all-cause death, MI, and stroke, independent of the severity of renal impairment.'
Journal of the American Society of Nephrology 2007; advance online publication